Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients

Carr, Edward J; Wu, Mary; Harvey, Ruth; Wall, Emma C; Kelly, Gavin; Hussain, Saira; Howell, Michael; Kassiotis, George; Swanton, Charles; Gandhi, Sonia; Bauer, David L.V.; Billany, Roseanne E; Graham-Brown, Matthew P M; Beckett, Joseph; Bull, Katherine; Shankar, Sushma; Henderson, Scott; Motallebzadeh, Reza; Salama, Alan D.; Harper, Lorraine; Mark, Patrick B.; McAdoo, Stephen P; Willicombe, Michelle; Beale, Rupert

doi:10.1016/s0140-6736(21)01854-7

Cited by 79 publications

(83 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functional humoral responses after vaccination were assessed in all patients using a high- ). The distribution of neutralising antibody (NAb) titres (NAbT) was categorised as undetectable (<40), moderate , and high (>256), as per previously published reports using the same neutralisation assay [27][28][29] .…”

Section: Nab Responses Following Covid-19 Vaccinesmentioning

confidence: 99%

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

Fendler¹,

Shepherd²,

Au³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable neutralizing antibody titers (NAbT) against SARS-CoV-2 variants of concern (VOCs) vs wild-type (WT). Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT vs solid cancers against both WT and VOCs. In comparison with individuals without cancer, patients with haematological, but not solid, malignancies had reduced NAb responses. Seroconversion showed poor concordance with NAbT against VOCs. Prior SARS-CoV-2 infection boosted NAb response including against VOCs, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T-cell responses were detected in 80% of patients, and were comparable between vaccines or cancer types. Our results have implications for the management of cancer patients during the ongoing COVID-19 pandemic.

show abstract

Section: Nab Responses Following Covid-19 Vaccinesmentioning

confidence: 99%

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

Fendler¹,

Shepherd²,

Au³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, across all variants tested, antibody titres following BNT162b2 vaccination were similar between patients receiving dialysis and healthy controls, whereas vaccination with AZD1222 was less efficacious in patients receiving dialysis. Patients who received AZD1222 had significantly lower neutralizing antibody responses against variants such as the Delta variant compared with healthy controls 4 . The difference between the AZD1222 and BNT162b2 vaccines was less pronounced in patients with previous infection treated with dialysis.…”

Section: Box 1 Mitigation Of Infection and Severe Disease Risk In Patients Treated With Dialysismentioning

confidence: 93%

“…However, whether the immune response in these patients is diminished and less protective than that of matched healthy controls remains a matter of debate. A recent interim analysis of a large cohort study compared the induction of SARS-CoV-2-neutralizing antibodies in COVID-19-naive patients treated with dialysis after two doses of either the mRNA-based BNT162b2 vaccine ( n = 55) or the adenovirus-based AZD1222 vaccine ( n = 53), and healthy control participants ( n = 162) 4 . Interestingly, in patients receiving dialysis, the BNT162b2 vaccine induced higher titres of neutralizing antibodies against the wild-type virus and variants (for example, the Delta variant) than the AZD1222 vaccine 33 days after the second dose.…”

Section: Box 1 Mitigation Of Infection and Severe Disease Risk In Patients Treated With Dialysismentioning

confidence: 99%

COVID-19 vaccination in patients receiving dialysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Older people and those with multimorbidity mount weaker antibody responses to vaccination 10. Immunosuppressed people are at particularly high risk 1112. Furthermore, vaccine efficacy is expected to wane over time 13.…”

Section: Patient Selectionmentioning

confidence: 99%

Ronapreve for prophylaxis and treatment of covid-19

Sidebottom

2021

BMJ

View full text Add to dashboard Cite

On 20 August 2021, Ronapreve received conditional marketing authorisation for the prevention and treatment of covid-19 in the UK. 1 Ronapreve (REGEN-COV in the US) comprises two monoclonal antibodies, casirivimab and imdevimab, that target the SARS-CoV-2 spike protein to reduce the risk and severity of covid-19 in selected patients. 2 -5 Although Ronapreve's approval represents a welcome expansion in the armamentarium against covid-19, it also brings difficult questions about who should be eligible for treatment.

show abstract

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients

Cited by 79 publications

References 17 publications

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

COVID-19 vaccination in patients receiving dialysis

Ronapreve for prophylaxis and treatment of covid-19

Contact Info

Product

Resources

About